Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | RXRG | P48443 | 2/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573101 | 0.93 | RXRA (0.46) | RXRARXRBRXRGPOLA1KDM1A | |
| SCHEMBL26607136 | 0.93 | RXRA (0.46) | RXRARXRBRXRGPOLA1KDM1A | |
| SCHEMBL4654263 | 0.90 | RXRA (0.37) | RXRARXRBRXRGPOLA1TAAR1 | |
| SCHEMBL1496270 | 0.83 | MAPT (0.38) | RXRARXRBRXRGALDH1A1MAPK1 | |
| SCHEMBL6085848 | 0.82 | HTR2A (0.46) | RXRARXRBRXRGPOLA1 | |
| SCHEMBL8293241 | 0.78 | RXRA (0.51) | RXRARXRBRXRGTAAR1 | |
| SCHEMBL5706367 | 0.78 | RXRA (0.40) | RXRARXRBRXRG | |
| SCHEMBL6275679 | 0.77 | RXRA (0.47) | RXRARXRBRXRGPOLA1 | |
| SCHEMBL6785200 | 0.77 | MAPT (0.46) | RXRAALDH1A1MAPK1CYP3A4KDM4E | |
| SCHEMBL5706327 | 0.76 | RXRA (0.51) | RXRARXRBRXRGPOLA1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947671-B2 | Synthesis of naturally occuring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| US-7795260-B2 | Synthesis of naturally occurring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2010-09-14 | — | — | US | disclosed |
| US-20100216987-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | BARRASA VALENTIN MARTINEZ | 2010-08-26 | — | — | US | disclosed |
| US-7767659-B2 | Synthesis of naturally occurring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2010-08-03 | — | — | US | disclosed |
| US-20090163507-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20070093658-A1 | Synthesis of naturally occcuring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2007-04-26 | — | — | US | disclosed |
| US-7026487-B2 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity | ALLERGAN, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1401427-A4 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM | AGOURON PHARMA (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | BEARD RICHARD L (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1401427-A2 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM | Agouron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | ALLERGAN SALES, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6613917-B1 | Retinoid agonist, antagonist or negative hormone-like biological activity | ALLERGAN, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-1265848-A2 | AMINES SUBSTITUTED WITH A DIHYDRONAPHTHALENYL, CRHOMENYL, OR THIOCHROMENYL GROUP, AN ARYL OR HETEROARYL GROUP AND AN ALKYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002098363-A2 | NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2001070668-A2 | AMINES SUBSTITUTED WITH A DIHYDRONAPHTHALENYL, CRHOMENYL, OR THIOCHROMENYL GROUP, AN ARYL OR HETEROARYL GROUP AND AN ALKYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216987-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | NQO1, HCCS, NME1 | RXRA 3053/4885RXRB 2976/4885RXRG 2402/4885 |
| US-20070093658-A1 | Synthesis of naturally occcuring ecteinascidins and related compounds | NQO1, EDF1, RCN1 | RXRA 3270/4885RXRB 2972/4885RXRG 2161/4885 |
| US-20090163507-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | NQO1, HCCS, NME1 | RXRA 3053/4885RXRB 2976/4885RXRG 2402/4885 |
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | RXRA 13/4885RXRB 12/4885RXRG 17/4885 |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | RXRA 13/4885RXRB 12/4885RXRG 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.